1 Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. USA95, 13363-13383 (1998).
2 Weissmann, C. Birth of a prion: spontaneous generation revisited. Cell122, 165-168 (2005).
3 Wadsworth, J. D. & Collinge, J. Update on human prion disease. Biochim. Biophys. Acta1772, 598-609 (2007).
4 Uttley, L., Carroll, C., Wong, R., Hilton, D. A. & Stevenson, M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect. Dis.20, e2-e10 (2020).
5 Abrahantes, J. C. et al. Classification of sporadic Creutzfeldt-Jakob disease based on clinical and neuropathological characteristics. Eur. J. Epidemiol.22, 457-465 (2007).
6 Mead, S., Lloyd, S. & Collinge, J. Genetic Factors in Mammalian Prion Diseases. Annu. Rev. Genet.53, 117-147 (2019).
7 Collinge, J. et al. Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet367, 2068-2074 (2006).
8 Will, R. G. et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet347, 921-925 (1996).
9 Ghani, A. C., Donnelly, C. A., Ferguson, N. M. & Anderson, R. M. Updated projections of future vCJD deaths in the UK. BMC Infect. Dis.3, 4 (2003).
10 Brown, P. et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg. Infect. Dis.18, 901-907 (2012).
11 Bernoulli, C. et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet1, 478-479 (1977).
12 El Hachimi, K. H., Chaunu, M. P., Cervenakova, L., Brown, P. & Foncin, J. F. Putative neurosurgical transmission of Creutzfeldt-Jakob disease with analysis of donor and recipient: agent strains. C. R. Acad. Sci. III320, 319-328 (1997).
13 Mahillo-Fernandez, I. et al. Surgery and risk of sporadic Creutzfeldt-Jakob disease in Denmark and Sweden: registry-based case-control studies. Neuroepidemiology31, 229-240 (2008).
14 McDonnell, G. et al. Cleaning, disinfection and sterilization of surface prion contamination. J. Hosp. Infect.85, 268-273 (2013).
15 Taylor, D. M. Decontamination of Creutzfeldt-Jakob disease agent. Ann. Neurol.20, 749-750 (1986).
16 Tateishi, J., Tashima, T. & Kitamoto, T. Practical methods for chemical inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol. Immunol.35, 163-166 (1991).
17 Botsios, S., Tittman, S. & Manuelidis, L. Rapid chemical decontamination of infectious CJD and scrapie particles parallels treatments known to disrupt microbes and biofilms. Virulence6, 787-801 (2015).
18 Taylor, D. M. Autoclaving standards for Creutzfeldt-Jakob disease agent. Ann. Neurol.22, 557-558 (1987).
19 Sakudo, A., Yamashiro, R. & Harata, C. Effect of Non-Concentrated and Concentrated Vaporized Hydrogen Peroxide on Scrapie Prions. Pathogens9, 947 (2020).
20 Fichet, G. et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet364, 521-526 (2004).
21 Ding, N. et al. Kinetics of ozone inactivation of infectious prion protein. Appl. Environ. Microbiol.79, 2721-2730 (2013).
22 Telling, G. C. et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev.10, 1736-1750 (1996).
23 Reed, J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hygiene27, 493-497 (1938).
24 Ding, N. et al. Ozone inactivation of infectious prions in rendering plant and municipal wastewaters. Sci. Total Environ.470-471, 717-725 (2014).
25 Johnson, C. J., Gilbert, P. U., McKenzie, D., Pedersen, J. A. & Aiken, J. M. Ultraviolet-ozone treatment reduces levels of disease-associated prion protein and prion infectivity. BMC Res. Notes2, 121 (2009).
26 Collinge, J. & Clarke, A. R. A general model of prion strains and their pathogenicity. Science318, 930-936 (2007).
27 Wadsworth, J. D., Asante, E. A. & Collinge, J. Review: contribution of transgenic models to understanding human prion disease. Neuropathol. Appl. Neurobiol.36, 576-597 (2010).
28 Mudd, J. B., Leavitt, R., Ongun, A. & McManus, T. T. Reaction of ozone with amino acids and proteins. Atmos Environ.3, 669-682 (1969).
29 McEvoy, B. & Rowan, N. J. Terminal sterilization of medical devices using vaporized hydrogen peroxide: a review of current methods and emerging opportunities. J. Appl. Microbiol.127, 1403-1420 (2019).
30 Glaze, W. H., Kang, J.-W. & Chapin, D. H. The chhemistry of water treatment processes involving ozone, hydrogen peroxide and ultraviolet radiation. Ozone Sci. Eng.9, 335-352 (1987).
31 Hara, H. et al. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice. J. Virol.92, e01368-17 (2018).